This article based on the Oct 3, 2024 Insights FAWG Forum explores the potential for artificial intelligence (AI) to transform Medical Affairs, focusing on medical insights.
In this webinar, we will discuss the regulatory bodies such as the Food and Drug Administration (FDA) and European Medicines Agency (EMA) are increasingly recognising the value of supplementing clinical trial data with real-world evidence to improve understanding of drug performance in the healthcare setting.
Experts from Pfizer and Veeva explore a recent Veeva Pulse Report showing that targeted scientific outreach is associated with 40% faster treatment adoption.
In this podcast, experts explore the many challenges associated with the operationalization of global Integrated Evidence Generation Planning (IEGP) at local levels.
In this webinar, we will share a comprehensive and practical overview of how Artificial Intelligence (AI) can be integrated into various functions of Medical Affairs.
What makes a publication interesting or impactful? Is it number of citations? Sentiment among important stakeholders? Relevance to the largest patient population? Popular news attention? The answer depends on your strategy. Here we speak with experts from Altmetric about 10 publications that are impactful for different reasons.
Take advantage of alternative impact metrics that better reflect the multidimensional nature of today’s research dissemination and consumption.
Dig into best practices for measuring the operational effectiveness of Medical Affairs teams, emphasizing the importance of establishing a strong foundation of data and metrics to demonstrate impact and value within pharmaceutical organizations.
In this webinar, we will share new data showing that while medical affairs is increasing in importance, it is still struggling to reach a consensus around medical impact metrics. However, measuring medical impact is no longer a choice; it’s a necessity for medical to communicate its value as a business function and better demonstrate its contributions to successful patient outcomes.
MAPS’ 2024 Benchmark Report is based on findings from 32 organizations in Pharma and MedTech and reflects broad leadership thinking about the current and future states of AI capabilities and challenges in Medical Affairs.